Mundipharma Headquarters & Office Locations

Mundipharma is headquartered in Cambridge, England, United Kingdom. Founded in 1952, the company has 25 recorded locations across 6+ countries and employs approximately 2,705 people worldwide.

Where is Mundipharma's main office?

Mundipharma's main headquarters office is located at Cambridge, England cb4 0ab, United Kingdom. This is the company's primary corporate address.

Mundipharma regional offices

Beyond its headquarters in Cambridge, Mundipharma has recorded locations in United Kingdom, France, Germany, Switzerland, The Netherlands and United States.

Mundipharma contact information

The main switchboard for Mundipharma headquarters can be reached at +44 1223 424211. Official website: mundipharma.com.

What does Mundipharma do?

The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.